BRD2 and breast cancer: Similarly, the use of low-dose intravaginal estriol (0.005%) has also been evaluated in women with breast cancer undergoing adjuvant treatment with AI, with evidence of safety in this replacement therapy, as there was no detection of increased serum estradiol levels or hormonal levels of FSH and LH in treated patients [8].